1
|
Zhao W, Zhou LY, Kong J, Huang ZH, Gao YD, Zhang ZX, Zhou YJ, Wu RY, Xu HJ, An SJ. Expression of recombinant human Apolipoprotein A-I Milano in Nicotiana tabacum. BIORESOUR BIOPROCESS 2023; 10:4. [PMID: 38647895 PMCID: PMC10992485 DOI: 10.1186/s40643-023-00623-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2022] [Accepted: 01/02/2023] [Indexed: 01/22/2023] Open
Abstract
Apolipoprotein A-IMilano (Apo A-IMilano) is a natural mutant of Apolipoprotein. It is currently the only protein that can clear arterial wall thrombus deposits and promptly alleviate acute myocardial ischemia. Apo A-IMilano is considered as the most promising therapeutic protein for treating atherosclerotic diseases without obvious toxic or side effects. However, the current biopharmaceutical platforms are not efficient for developing Apo A-IMilano. The objectives of this research were to express Apo A-IMilano using the genetic transformation ability of N. tabacum. The method is to clone the coding sequence of Apo A-IMilano into the plant binary expression vector pCHF3 with a Flag/His6/GFP tag. The constructed plasmid was transformed into N. tabacum by a modified agrobacterium-mediated method, and transformants were selected under antibiotic stress. PCR, RT-qPCR, western blot and co-localization analysis was used to further verify the resistant N. tabacum. The stable expression and transient expression of N. tabacum were established, and the pure product of Apo A-IMilano was obtained through protein A/G agarose. The results showed that Apo A-IMilano was expressed in N. tabacum with a yield of 0.05 mg/g leaf weight and the purity was 90.58% ± 1.65. The obtained Apo A-IMilano protein was subjected to amino acid sequencing. Compared with the theoretical sequence of Apo A-IMilano, the amino acid coverage was 86%, it is also found that Cysteine replaces Arginine at position 173, which indicates that Apo A-IMilano, a mutant of Apo A-I, is accurately expressed in N. tabacum. The purified Apo A-IMilano protein had a lipid binding activity. The established genetic modification N. tabacum will provide a cost-effective system for the production of Apo A-IMilano. Regarding the rapid propagation of N. tabacum, this system provides the possibility of large-scale production and accelerated clinical translation of Apo A-IMilano.
Collapse
Affiliation(s)
- Wei Zhao
- Hebei Provincial Engineering Laboratory of Plant Bioreactor Preparation Technology, Hebei University of Chinese Medicine, No. 326 Xinshi South Road, Shijiazhuang, 050090, Hebei, China
| | - Lu-Yang Zhou
- Hebei Provincial Engineering Laboratory of Plant Bioreactor Preparation Technology, Hebei University of Chinese Medicine, No. 326 Xinshi South Road, Shijiazhuang, 050090, Hebei, China
| | - Jing Kong
- Hebei Provincial Engineering Laboratory of Plant Bioreactor Preparation Technology, Hebei University of Chinese Medicine, No. 326 Xinshi South Road, Shijiazhuang, 050090, Hebei, China
- School of Nursing of Hebei University of Chinese Medicine, No. 326 Xinshi South Road, Shijiazhuang, 050090, Hebei, China
| | - Ze-Hao Huang
- Hebei Provincial Engineering Laboratory of Plant Bioreactor Preparation Technology, Hebei University of Chinese Medicine, No. 326 Xinshi South Road, Shijiazhuang, 050090, Hebei, China
| | - Ya-Di Gao
- Hebei Provincial Engineering Laboratory of Plant Bioreactor Preparation Technology, Hebei University of Chinese Medicine, No. 326 Xinshi South Road, Shijiazhuang, 050090, Hebei, China
| | - Zhong-Xia Zhang
- Hebei Provincial Engineering Laboratory of Plant Bioreactor Preparation Technology, Hebei University of Chinese Medicine, No. 326 Xinshi South Road, Shijiazhuang, 050090, Hebei, China
- School of Nursing of Hebei University of Chinese Medicine, No. 326 Xinshi South Road, Shijiazhuang, 050090, Hebei, China
| | - Yong-Jie Zhou
- Hebei Provincial Engineering Laboratory of Plant Bioreactor Preparation Technology, Hebei University of Chinese Medicine, No. 326 Xinshi South Road, Shijiazhuang, 050090, Hebei, China
| | - Ruo-Yu Wu
- Hebei Provincial Engineering Laboratory of Plant Bioreactor Preparation Technology, Hebei University of Chinese Medicine, No. 326 Xinshi South Road, Shijiazhuang, 050090, Hebei, China
| | - Hong-Jun Xu
- Hebei Provincial Engineering Laboratory of Plant Bioreactor Preparation Technology, Hebei University of Chinese Medicine, No. 326 Xinshi South Road, Shijiazhuang, 050090, Hebei, China.
| | - Sheng-Jun An
- Hebei Provincial Engineering Laboratory of Plant Bioreactor Preparation Technology, Hebei University of Chinese Medicine, No. 326 Xinshi South Road, Shijiazhuang, 050090, Hebei, China.
| |
Collapse
|
2
|
Wang X, Hunter AK, Mozier NM. Host cell proteins in biologics development: Identification, quantitation and risk assessment. Biotechnol Bioeng 2009; 103:446-58. [PMID: 19388135 DOI: 10.1002/bit.22304] [Citation(s) in RCA: 158] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Host cell proteins (HCPs) are those produced or encoded by the organisms and unrelated to the intended recombinant product. Some are necessary for growth, survival, and normal cellular processing whereas others may be non-essential, simply carried along as baggage. Like the recombinant product, HCPs may also be modified by the host with a number of post-translational modifications. Regardless of the utility, or lack thereof, HCPs are undesirable in the final drug substance. Though commonly present in small quantities (parts per million expressed as nanograms per milligrams of the intended recombinant protein) much effort and cost is expended by industry to remove them. The purpose of this review is to summarize what is of relevance in regards to the biology, the impact of genomics and proteomics on HCP evaluation, the regulatory expectations, analytical approaches, and various methodologies to remove HCPs with bioprocessing. Historical data, bioinformatics approaches and industrial case study examples are provided. Finally, a proposal for a risk assessment tool is provided which brings these facets together and proposes a means for manufacturers to classify and organize a control strategy leading to meaningful product specifications.
Collapse
Affiliation(s)
- Xing Wang
- Pfizer, Inc., Global Biologics, Chesterfield, Missouri 63017, USA
| | | | | |
Collapse
|